Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a clinical-stage biotech firm, will hold a conference call on May 9, 2024, to discuss its Q1 financial results and provide a corporate update. The company, known for developing the immunotherapeutic agent pelareorep for various cancers, has seen promising results in clinical trials and holds Fast Track designation for metastatic breast and pancreatic cancer treatments.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
